nach oben

Archives of Virology

Erschienen in:

01.07.2012 | Original Article

(−)-Epigallocatechin-3-gallate inhibits the replication cycle of hepatitis C virus

verfasst von: Chao Chen, Hui Qiu, Jian Gong, Qing Liu, Han Xiao, Xin-Wen Chen, Bin-Lian Sun, Rong-Ge Yang

Erschienen in: Archives of Virology | Ausgabe 7/2012

Einloggen, um Zugang zu erhalten

Abstract

(−)-Epigallocatechin-3-gallate (EGCG) is the most abundant catechin in green tea. In this study, we found that hepatitis C virus (HCV) infection was significantly suppressed by EGCG in an HCV cell culture (HCVcc) system using a JFH1-GFP chimeric virus, with a 50 % effective concentration (EC₅₀) of 17.9 μM. The inhibitory activity of EGCG was confirmed by monitoring HCV RNA and protein expression levels in Huh7.5.1 cells infected with the JFH1 virus. Moreover, we demonstrated that the inhibitory mechanisms of EGCG were attributable to the suppression of both the HCV entry and RNA replication steps, although EGCG had little effect on translation directed by the viral internal ribosome entry site (IRES). Furthermore, HCV could be rapidly eliminated from cell cultures after two and five passages in the presence of 50 and 25 μM EGCG, respectively. These results indicate that EGCG is a potential candidate as a preventive and antiviral drug for HCV infection.

Ahn WS, Yoo J, Huh SW, Kim CK, Lee JM, Namkoong SE, Bae SM, Lee IP (2003) Protective effects of green tea extracts (polyphenon E and EGCG) on human cervical lesions. Eur J Cancer Prev 12:383–390PubMedCrossRef

Babich H, Krupka ME, Nissim HA, Zuckerbraun HL (2005) Differential in vitro cytotoxicity of (−)-epicatechin gallate (ECG) to cancer and normal cells from the human oral cavity. Toxicol In Vitro 19:231–242PubMedCrossRef

Baldick CJ, Wichroski MJ, Pendri A, Walsh AW, Fang J, Mazzucco CE, Pokornowski KA, Rose RE, Eggers BJ, Hsu M, Zhai W, Zhai G, Gerritz SW, Poss MA, Meanwell NA, Cockett MI, Tenney DJ (2010) A novel small molecule inhibitor of hepatitis C virus entry. PLoS Pathog 6(9):e24142CrossRef

Bartosch B, Dubuisson J, Cosset FL (2003) Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 197:633–642PubMedCrossRef

Cabrera C, Artacho R, Gimenez R (2006) Beneficial effects of green tea–a review. J Am Coll Nutr 25:79–99PubMed

Calland N, Albecka A, Belouzard S, Wychowski C, Duverlie G, Descamps V, Hober D, Dubuisson J, Rouille Y, Seron K (2012) (−)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry. Hepatology 55:720–729PubMedCrossRef

Chang LK, Wei TT, Chiu YF, Tung CP, Chuang JY, Hung SK, Li C, Liu ST (2003) Inhibition of Epstein-Barr virus lytic cycle by (−)-epigallocatechin gallate. Biochem Biophys Res Commun 301:1062–1068PubMedCrossRef

Ciesek S, von Hahn T, Colpitts CC, Schang LM, Friesland M, Steinmann J, Manns MP, Ott M, Wedemeyer H, Meuleman P, Pietschmann T, Steinmann E (2011) The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. Hepatology 54:1947–1955PubMedCrossRef

Crockett SD, Keeffe EB (2005) Natural history and treatment of hepatitis B virus and hepatitis C virus coinfection. Ann Clin Microbiol Antimicrob 4:13PubMedCrossRef

10.

Dona M, Dell’Aica I, Calabrese F, Benelli R, Morini M, Albini A, Garbisa S (2003) Neutrophil restraint by green tea: inhibition of inflammation, associated angiogenesis, and pulmonary fibrosis. J Immunol 170:4335–4341PubMed

11.

Drummer HE, Maerz A, Poumbourios P (2003) Cell surface expression of functional hepatitis C virus E1 and E2 glycoproteins. FEBS Lett 546:385–390PubMedCrossRef

12.

Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, Serrano-Wu MH, Langley DR, Sun JH, O’Boyle DR 2nd, Lemm JA, Wang C, Knipe JO, Chien C, Colonno RJ, Grasela DM, Meanwell NA, Hamann LG (2010) Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465:96–100PubMedCrossRef

13.

Gonzalez O, Fontanes V, Raychaudhuri S, Loo R, Loo J, Arumugaswami V, Sun R, Dasgupta A, French SW (2009) The heat shock protein inhibitor Quercetin attenuates hepatitis C virus production. Hepatology 50:1756–1764PubMedCrossRef

14.

Goueslain L, Alsaleh K, Horellou P, Roingeard P, Descamps V, Duverlie G, Ciczora Y, Wychowski C, Dubuisson J, Rouille Y (2010) Identification of GBF1 as a cellular factor required for hepatitis C virus RNA replication. J Virol 84:773–787PubMedCrossRef

15.

Han Q, Xu C, Wu C, Zhu W, Yang R, Chen X (2009) Compensatory mutations in NS3 and NS5A proteins enhance the virus production capability of hepatitis C reporter virus. Virus Res 145:63–73PubMedCrossRef

16.

He W, Li LX, Liao QJ, Liu CL, Chen XL (2011) Epigallocatechin gallate inhibits HBV DNA synthesis in a viral replication—inducible cell line. World J Gastroenterol 17:1507–1514PubMedCrossRef

17.

Ho HY, Cheng ML, Weng SF, Leu YL, Chiu DT (2009) Antiviral effect of epigallocatechin gallate on enterovirus 71. J Agric Food Chem 57:6140–6147PubMedCrossRef

18.

Hsu M, Zhang J, Flint M, Logvinoff C, Cheng-Mayer C, Rice CM, McKeating JA (2003) Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci USA 100:7271–7276PubMedCrossRef

19.

Huang W, Ding L, Huang Q, Hu H, Liu S, Yang X, Hu X, Dang Y, Shen S, Li J, Ji X, Jiang S, Liu JO, Yu L (2010) Carbonyl reductase 1 as a novel target of (−)-epigallocatechin gallate against hepatocellular carcinoma. Hepatology 52:703–714PubMedCrossRef

20.

Isaacs CE, Wen GY, Xu W, Jia JH, Rohan L, Corbo C, Di Maggio V, Jenkins EC Jr, Hillier S (2008) Epigallocatechin gallate inactivates clinical isolates of herpes simplex virus. Antimicrob Agents Chemother 52:962–970PubMedCrossRef

21.

Jiang F, Chen W, Yi K, Wu Z, Si Y, Han W, Zhao Y (2011) The evaluation of catechins that contain a galloyl moiety as potential HIV-1 integrase inhibitors. Clin Immunol 137:347–356CrossRef

22.

Kanadzu M, Lu Y, Morimoto K (2006) Dual function of (–)-epigallocatechin gallate (EGCG) in healthy human lymphocytes. Cancer Lett 241:250–255PubMedCrossRef

23.

Kato T, Date T, Murayama A, Morikawa K, Akazawa D, Wakita T (2006) Cell culture and infection system for hepatitis C virus. Nat Protoc 1:2334–2339PubMedCrossRef

24.

Kawai K, Tsuno NH, Kitayama J, Okaji Y, Yazawa K, Asakage M, Sasaki S, Watanabe T, Takahashi K, Nagawa H (2005) Epigallocatechin gallate induces apoptosis of monocytes. J Allergy Clin Immunol 115:186–191PubMedCrossRef

25.

Khan N, Afaq F, Saleem M, Ahmad N, Mukhtar H (2006) Targeting multiple signaling pathways by green tea polyphenol (−)-epigallocatechin-3-gallate. Cancer Res 66:2500–2505PubMedCrossRef

26.

Kieffer TL, Kwong AD, Picchio GR (2010) Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). J Antimicrob Chemother 65:202–212PubMedCrossRef

27.

Kim CS, Jung JH, Wakita T, Yoon SK, Jang SK (2007) Monitoring the antiviral effect of alpha interferon on individual cells. J Virol 81:8814–8820PubMedCrossRef

28.

Kwong AD, McNair L, Jacobson I, George S (2008) Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors. Curr Opin Pharmacol 8:522–531PubMedCrossRef

29.

Li S, Hattori T, Kodama EN (2011) Epigallocatechin gallate inhibits the HIV reverse transcription step. Antivir Chem Chemother 21:239–243PubMedCrossRef

30.

Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM (2005) Complete replication of hepatitis C virus in cell culture. Science 309:623–626PubMedCrossRef

31.

Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R (1999) Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110–113PubMedCrossRef

32.

Moradpour D, Penin F, Rice CM (2007) Replication of hepatitis C virus. Nat Rev Microbiol 5:453–463PubMedCrossRef

33.

Muir AJ (2011) Telaprevir for the treatment of chronic hepatitis C infection. Expert Rev Anti Infect Ther 9:1105–1114PubMedCrossRef

34.

Munir S, Saleem S, Idrees M, Tariq A, Butt S, Rauff B, Hussain A, Badar S, Naudhani M, Fatima Z, Ali M, Ali L, Akram M, Aftab M, Khubaib B, Awan Z (2010) Hepatitis C treatment: current and future perspectives. Virol J 7:296PubMedCrossRef

35.

Nakagawa S, Umehara T, Matsuda C, Kuge S, Sudoh M, Kohara M (2007) Hsp90 inhibitors suppress HCV replication in replicon cells and humanized liver mice. Biochem Biophys Res Commun 353:882–888PubMedCrossRef

36.

Noda C, He J, Takano T, Tanaka C, Kondo T, Tohyama K, Yamamura H, Tohyama Y (2007) Induction of apoptosis by epigallocatechin-3-gallate in human lymphoblastoid B cells. Biochem Biophys Res Commun 362:951–957PubMedCrossRef

37.

Okamoto T, Nishimura Y, Ichimura T, Suzuki K, Miyamura T, Suzuki T, Moriishi K, Matsuura Y (2006) Hepatitis C virus RNA replication is regulated by FKBP8 and Hsp90. EMBO J 25:5015–5025PubMedCrossRef

38.

Pietschmann T, Lohmann V, Kaul A, Krieger N, Rinck G, Rutter G, Strand D, Bartenschlager R (2002) Persistent and transient replication of full-length hepatitis C virus genomes in cell culture. J Virol 76:4008–4021PubMedCrossRef

39.

Roh C, Jo SK (2011) (−)-Epigallocatechin gallate inhibits hepatitis C virus (HCV) viral protein NS5B. Talanta 85:2639–2642PubMedCrossRef

40.

Schaller T, Appel N, Koutsoudakis G, Kallis S, Lohmann V, Pietschmann T, Bartenschlager R (2007) Analysis of hepatitis C virus superinfection exclusion by using novel fluorochrome gene-tagged viral genomes. J Virol 81:4591–4603PubMedCrossRef

41.

She Y, Liao Q, Chen X, Ye L, Wu Z (2008) Hepatitis C virus (HCV) NS2 protein up-regulates HCV IRES-dependent translation and down-regulates NS5B RdRp activity. Arch Virol 153:1991–1997PubMedCrossRef

42.

Shepard CW, Finelli L, Alter MJ (2005) Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5:558–567PubMedCrossRef

43.

Song JM, Lee KH, Seong BL (2005) Antiviral effect of catechins in green tea on influenza virus. Antiviral Res 68:66–74PubMedCrossRef

44.

Stapleton PD, Shah S, Anderson JC, Hara Y, Hamilton-Miller JM, Taylor PW (2004) Modulation of beta-lactam resistance in Staphylococcus aureus by catechins and gallates. Int J Antimicrob Agents 23:462–467PubMedCrossRef

45.

Steinmann E, Whitfield T, Kallis S, Dwek RA, Zitzmann N, Pietschmann T, Bartenschlager R (2007) Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus. Hepatology 46:330–338PubMedCrossRef

46.

Tao W, Xu C, Ding Q, Li R, Xiang Y, Chung J, Zhong J (2009) A single point mutation in E2 enhances hepatitis C virus infectivity and alters lipoprotein association of viral particles. Virology 395:67–76PubMedCrossRef

47.

Timm J, Roggendorf M (2007) Sequence diversity of hepatitis C virus: implications for immune control and therapy. World J Gastroenterol 13:4808–4817PubMed

48.

Tsubota A, Fujise K, Namiki Y, Tada N (2011) Peginterferon and ribavirin treatment for hepatitis C virus infection. World J Gastroenterol 17:419–432PubMedCrossRef

49.

Ullmann U, Haller J, Decourt JP, Girault N, Girault J, Richard-Caudron AS, Pineau B, Weber P (2003) A single ascending dose study of epigallocatechin gallate in healthy volunteers. J Int Med Res 31:88–101PubMed

50.

Verucchi G, Calza L, Manfredi R, Chiodo F (2004) Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management. Infection 32:33–46PubMedCrossRef

51.

Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Krausslich HG, Mizokami M, Bartenschlager R, Liang TJ (2005) Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11:791–796PubMedCrossRef

52.

Weber JM, Ruzindana-Umunyana A, Imbeault L, Sircar S (2003) Inhibition of adenovirus infection and adenain by green tea catechins. Antiviral Res 58:167–173PubMedCrossRef

53.

Wu Y, Liao Q, Yang R, Chen X, Chen X (2011) A novel luciferase and GFP dual reporter virus for rapid and convenient evaluation of hepatitis C virus replication. Virus Res 155:406–414PubMedCrossRef

54.

Xu J, Wang J, Deng F, Hu Z, Wang H (2008) Green tea extract and its major component epigallocatechin gallate inhibits hepatitis B virus in vitro. Antiviral Res 78:242–249PubMedCrossRef

55.

Yamaguchi K, Honda M, Ikigai H, Hara Y, Shimamura T (2002) Inhibitory effects of (−)-epigallocatechin gallate on the life cycle of human immunodeficiency virus type 1 (HIV-1). Antiviral Res 53:19–34PubMedCrossRef

56.

Yin Z, Henry EC, Gasiewicz TA (2009) (−)-Epigallocatechin-3-gallate is a novel Hsp90 inhibitor. Biochemistry 48:336–345PubMedCrossRef

57.

Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, Wieland SF, Uprichard SL, Wakita T, Chisari FV (2005) Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA 102:9294–9299PubMedCrossRef

58.

Zuo G, Li Z, Chen L, Xu X (2007) Activity of compounds from Chinese herbal medicine Rhodiola kirilowii (Regel) Maxim against HCV NS3 serine protease. Antiviral Res 76:86–92PubMedCrossRef

Titel: (−)-Epigallocatechin-3-gallate inhibits the replication cycle of hepatitis C virus
verfasst von: Chao Chen
Hui Qiu
Jian Gong
Qing Liu
Han Xiao
Xin-Wen Chen
Bin-Lian Sun
Rong-Ge Yang
Publikationsdatum: 01.07.2012
Verlag: Springer Vienna
Erschienen in: Archives of Virology / Ausgabe 7/2012
Print ISSN: 0304-8608
Elektronische ISSN: 1432-8798
DOI: https://doi.org/10.1007/s00705-012-1304-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2012

Identification of three new type-specific antigen epitopes in the capsid protein of porcine circovirus type 1

Development of a multiplex polymerase chain reaction for simultaneous detection of wheat viruses and a phytoplasma in China

Nucleotide sequence of a chickpea chlorotic stunt virus relative that infects pea and faba bean in China

Ratification vote on taxonomic proposals to the International Committee on Taxonomy of Viruses (2012)

Molecular variation and recombination in RNA segment 10 of rice black-streaked dwarf virus isolated from China during 2007-2010